Given that point mutations are common among DSD patients (such as inactivating mutations in the SRY gene, missense variants in NR5A1, and single-nucleotide mutations in FOXL2), TALENs and ZFNs are particularly suitable for precise correction of such point mutations. Here, SRY is linked to disorder of sexual differentiation.